Sensei Biotherapeutics FY EPS $(1.22) Up From $(1.58) YoY; 2023 Year End Cash, Cash Equivalents And Marketable Securities Of $65.8M Is Expected To Provide Cash Runway Into Fourth Quarter Of 2025
Company Profile
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.